Restricted accessResearch articleFirst published online 2018-7
Improvement of self-reported functional scores and thickening of quadriceps and femoral intercondylar cartilage under ultrasonography after single intra-articular injection of a novel cross-linked hyaluronic acid in the treatment of knee osteoarthritis
Most studies used hyaluronic acid (HA) requiring 3–5 intra-articular injections (IAJ) for knee osteoarthritis (KOA).
OBJECTIVE:
We evaluated the efficacy of a single IAJ of a novel HA by measuring the thickness of quadriceps and femoral intercondylar cartilage (FIC) under ultrasonography (US) in addition to subjective self-reported measures.
METHODS:
Forty-nine patients with KOA (Kellgren-Lawrence grades 2–3) received unilateral IAJ of HYAJOINT Plus to the worse knee and were assessed at baseline and 1, 3 and 6-months after IAJ. Outcome measures were the (1) Visual Analog Scale for pain (VAS), (2) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), (3) Lequesne’s Index, (4) single-leg-stance duration (5) thigh circumference, and (6) thickness of quadriceps and FIC under US.
RESULTS:
Forty-six patients completed the 6-month-follow-up study. All outcome measures improved significantly after HA injection ( 0.001). Both VAS and WOMAC-pain subscale scores improved significantly at 1, 3, and 6 months ( 0.01). The US thickness of the quadriceps and FIC improved significantly at both 3 and 6 months ( 0.05). The Lequesne’s index, single-leg-stance and thigh circumference improved significantly at 6 months ( 0.01).
CONCLUSIONS
: HYAJOINT Plus is effective both subjectively and objectively for 6 months and is safe as a treatment for KOA.
BrooksPM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Current Opinion in Rheumatology.2002; 14(5): 573-7.
2.
National Collaborating Centre for Chronic C. National Institute for Health and Clinical Excellence: Guidance. Osteoarthritis: National Clinical Guideline for Care and Management in Adults. London: Royal College of Physicians (UK) Royal College of Physicians of London. 2008.
3.
van SaaseJLvan RomundeLKCatsAVandenbrouckeJPValkenburgHA. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Annals of the Rheumatic Diseases.1989; 48(4): 271-80.
4.
ChouCLLoYTLiuFWHaungLLChenJJ. The Therapeutic Effects of Intra-articular Hyaluronic Acid on the Physical Functioning of Patients with Knee Osteoarthritis: A Preliminary Report. Taiwan Journal of Physical Medicine and Rehabilitation.2012; 40(2): 77-83.
5.
BuckwalterJAStanishWDRosierRNSchenckRC, Jr.DennisDACouttsRD. The increasing need for nonoperative treatment of patients with osteoarthritis. Clinical Orthopaedics and Related Research.2011; 2001(385): 36-45.
6.
ChouCLSungWHLiuFWLeeHCHaungLLChenJJ. The Effect of Health Promotion with Physical Therapy and Intra-Articular Hyaluronic Acid for Knee Osteoarthritis. Taiwan Journal of Physical Medicine and Rehabilitation.2013; 41(1): 39-49.
7.
WuJJShihLYHsuHCChenTH. The double-blind test of sodium hyaluronate (ARTZ) on osteoarthritis knee. Zhonghua Yi Xue Za Zhi Chinese Medical Journal; Free China ed. 1997; 59(2): 99-106.
8.
CastellacciEPolieriT. Antalgic effect and clinical tolerability of hyaluronic acid in patients with degenerative diseases of knee cartilage: an outpatient treatment survey. Drugs Under Experimental and Clinical Research.2004; 30(2): 67-73.
9.
MorelandLW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Research & Therapy.2003; 5(2): 54-67.
10.
VitanzoPC, Jr.SennettBJ. Hyaluronans: is clinical effectiveness dependent on molecular weight? American Journal of Orthopedics (Belle Mead, NJ).2006; 35(9): 421-8.
11.
LisignoliGGrassiFZiniNToneguzziSPiacentiniAGuidolinD, et al. Anti-Fas-induced apoptosis in chondrocytes reduced by hyaluronan: evidence for CD44 and CD54 (intercellular adhesion molecule 1) invovement. Arthritis and Rheumatism.2001; 44(8): 1800-7.
12.
Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis and Rheumatism.2000; 43(9): 1905-15.
13.
ChevalierXJeroschJGoupillePvan DijkNLuytenFPScottDL, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Annals of the Rheumatic Diseases.2010; 69(1): 113-9.
14.
KocaIBoyaciATutogluABoyaciNOzkurA. The Relationship between Quadriceps Thickness, Radiological Staging, and Clinical Parameters in Knee Osteoarthritis. Journal of Physical Therapy Science.2014; 26(6): 931-6.
15.
ChenYJChenCHWangCLHuangMHChenTWLeeCL. Association between the severity of femoral condylar cartilage erosion related to knee osteoarthritis by ultrasonographic evaluation and the clinical symptoms and functions. Archives of Physical Medicine and Rehabilitation.2015; 96(5): 837-44.
16.
AltmanRAschEBlochDBoleGBorensteinDBrandtK, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis and Rheumatism.1986; 29(8): 1039-49.
17.
KellgrenJHLawrenceJS. Radiological assessment of osteo-arthrosis. Annals of the Rheumatic Diseases.1957; 16(4): 494-502.
18.
HuskissonEC. Measurement of pain. Lancet (London, England).1974; 2(7889): 1127-31.
19.
BellamyNBuchananWWGoldsmithCHCampbellJStittLW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. The Journal of Rheumatology.1988; 15(12): 1833-40.
20.
McConnellSKolopackPDavisAM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis and Rheumatism.2001; 45(5): 453-61.
21.
LequesneMGMeryCSamsonMGerardP. Indexes of severity for osteoarthritis of the hip and knee. Validation – value in comparison with other assessment tests. Scandinavian Journal of Rheumatology Supplement.1987; 65: 85-9.
22.
PetrellaRJDiSilvestroMDHildebrandC. Effects of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. Arch Intern Med.2002; 162(3): 292-8.
23.
RaynauldJPTorranceGWBandPAGoldsmithCHTugwellPWalkerV, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis and Cartilage.2002; 10(7): 506-17.
24.
WangCTLinYTChiangBLLinYHHouSM. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis and Cartilage.2006; 14(12): 1237-47.
25.
ElmorsySFunakoshiTSasazawaFTodohMTadanoSIwasakiN. Chondroprotective effects of high-molecular-weight cross-linked hyaluronic acid in a rabbit knee osteoarthritis model. Osteoarthritis and Cartilage.2014; 22(1): 121-7.
26.
DworkinRHTurkDCWyrwichKWBeatonDCleelandCSFarrarJT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. The Journal of Pain: Official Journal of the American Pain Society.2008; 9(2): 105-21.
27.
ColenSvan den BekeromMPMulierMHaverkampD. Hyaluronic acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy.2012; 26(4): 257-68.
28.
AngstFAeschlimannAMichelBAStuckiG. Minimal clinically important rehabilitation effects in patients with osteoarthritis of the lower extremities. The Journal of Rheumatology.2002; 29(1): 131-8.
29.
LequesneMG. The algofunctional indices for hip and knee osteoarthritis. The Journal of Rheumatology.1997; 24(4): 779-81.
30.
TerweeCBvan der SlikkeRMvan LummelRCBeninkRJMeijersWGde VetHC. Self-reported physical functioning was more influenced by pain than performance-based physical functioning in knee-osteoarthritis patients. Journal of Clinical Epidemiology.2006; 59(7): 724-31.
31.
PowersCMLandelRPerryJ. Timing and intensity of vastus muscle activity during functional activities in subjects with and without patellofemoral pain. Physical Therapy.1996; 76(9): 946-55; discussion 56-67.
32.
SaarakkalaSWarisPWarisVTarkiainenIKarvanenEAarnioJ, et al. Diagnostic performance of knee ultrasonography for detecting degenerative changes of articular cartilage. Osteoarthritis and Cartilage.2012; 20(5): 376-81.
33.
DingCCicuttiniFScottFCooleyHJonesG. Association between age and knee structural change: a cross sectional MRI based study. Annals of the Rheumatic Diseases.2005; 64(4): 549-55.
34.
KarvonenRLNegendankWGTeitgeRAReedAHMillerPRFernandez-MadridF. Factors affecting articular cartilage thickness in osteoarthritis and aging. The Journal of Rheumatology.1994; 21(7): 1310-8.
35.
KilicG,KilicEAkgulO,OzgocmenS. Ultrasonographic assessment of diurnal variation in the femoral condylar cartilage thickness in healthy young adults. American Journal of Physical Medicine & Rehabilitation.2015; 94(4): 297-303.
36.
YanCHChanWLYuenWHYungPSIpKYFanJC, et al. Efficacy and safety of hylan G-F 20 injection in treatment of knee osteoarthritis in Chinese patients: Results of a prospective, multicentre, longitudinal study. Hong Kong Medical Journal. 2015; 21(4): 327-32.
37.
CicuttiniFMWlukaABaileyMO’SullivanRPoonCYeungS, et al. Factors affecting knee cartilage volume in healthy men. Rheumatology (Oxford, England).2003; 42(2): 258-62.
38.
TunaSBalcıNÖzçakarL. The relationship between femoral cartilage thickness and muscle strength in knee osteoarthritis. ClinRheumatol. 2016; 35(8): 2073-7.
